Letters to The Editor — July 30, 2025
We write this letter as the President and the General Secretary, respectively, of the Ayurveda Medical Association of India (AMAI). While the question of 'integration' and the extent of clinical practice by practitioners of Ayurveda is open for public and policy-level discourse, the article, 'The medical boundaries for AYUSH practitioners' (Editorial page, July 29), unfairly singles out a globally recognised and government-approved system of medicine. It selectively quotes legal provisions, ignoring judicial pronouncements and the evolving nature of India's medical pluralism. Under Indian law, the terms doctor, vaidya, and hakim are considered synonymous when it comes to legitimate and recognised systems of medicine, including Ayurveda, Siddha, and Unani. This recognition has been established through court rulings and government notifications, especially after the enactment of The Indian Medicine Central Council Act, 1970, and policies supporting AYUSH. The article fails to acknowledge the acceptance Ayurveda enjoys today, as a scientific and evidence-based holistic medical system.
To present the prescribing rights of Ayurveda doctors as illegitimate or dangerous, without acknowledging the training, curriculum, and government regulation they follow, is not just irresponsible journalism but also a misrepresentation of facts aimed at misleading the public. Furthermore, implying that Ayurveda lacks a scientific foundation is both factually incorrect and intellectually dishonest. The article conveniently avoids the fact that many allopathic interventions have themselves not been subjected to rigorous traditional evidence hierarchies.
This kind of journalism undermines not only our national heritage but also the constitutional and legal framework that allows multiple systems of medicine to coexist and serve diverse public health needs in India.
Dr. K.S. Vishnu Namboothiri,
Dr. P.K. Haridas,
Thiruvananthapuram
New queen
That Divya Deshmukh is the new chess queen is wonderful news. Parents and teachers need to identify children with an interest in chess.
Gudipati Anirudh,
Secunderabad
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scroll.in
2 hours ago
- Scroll.in
As young Indians turn to AI ‘therapists', how confidential is their data?
This is the second of a two-part series. Read the first here. Imagine a stranger getting hold of a mental health therapist's private notes – and then selling that information to deliver tailored advertisements to their clients. That's practically what many mental healthcare apps might be doing. Young Indians are increasingly turning to apps and artificial intelligence-driven tools to address their mental health challenges – but have limited awareness about how these digital tools process user data. In January, the Centre for Internet and Society published a study based on 45 mental health apps – 28 from India and 17 from abroad – and found that 80% gathered user health data that they used for advertising and shared with third-party service providers. An overwhelming number of these apps, 87%, shared the data with law enforcement and regulatory bodies. The first article in this series had reported that some of these apps are especially popular with young Indian users, who rely on them for quick and easy access to therapy and mental healthcare support. Users had also told Scroll that they turned to AI-driven technology, such as ChatGPT, to discuss their feelings and get advice, however limited this may be compared to interacting with a human therapist. But they were not especially worried about data misuse. Keshav*, 21, reflected a common sentiment among those Scroll interviewed: 'Who cares? My personal data is already out there.' The functioning of Large Language Models, such as ChatGPT, is already under scrutiny. LLMs are 'trained' on vast amounts of data, either from the internet or provided by its trainers, to simulate human learning, problem solving and decision making. Sam Altman, CEO of OpenAI that built ChatGPT, said on a podcast in July that though users talk about personal matters with the chatbot, there are no legal safeguards protecting that information. 'People use it – young people, especially, use it – as a therapist, a life coach; having these relationship problems and [asking] what should I do?' he asked. 'And right now, if you talk to a therapist or a lawyer or a doctor about those problems, there's legal privilege for it. There's doctor-patient confidentiality, there's legal confidentiality, whatever. And we haven't figured that out yet for when you talk to ChatGPT.' Play He added: 'So if you go talk to ChatGPT about your most sensitive stuff and then there's like a lawsuit or whatever, we could be required to produce that, and I think that's very screwed up.' Therapists and experts said the ease of access of AI-driven mental health tools should not sideline privacy concerns. Clinical psychologist Rhea Thimaiah, who works at Kaha Mind, a collective that provides mental health services, emphasised that confidentiality is an essential part of the process of therapy. 'The therapeutic relationship is built on trust and any compromise in data security can very possibly impact a client's sense of safety and willingness to engage,' she said. 'Clients have a right to know how their information is being stored, who has access, and what protections are in place.' This is more than mere data – it is someone's memories, trauma and identity, Thimaiah said. 'If we're going to bring AI into this space, then privacy shouldn't be optional, it should be fundamental.' Srishti Srivastava, founder of AI-driven mental health app Infiheal, said that her firm collects user data to train its AI bot, but users can access the app even without signing up and also ask for their data to be deleted. Dhruv Garg, a tech policy lawyer at Indian Governance and Policy Project, said the risk lies not just in apps collecting data but in the potential downstream uses of that information. 'Even if it's not happening now, an AI platform in the future could start using your data to serve targeted ads or generate insights – commercial, political, or otherwise – based on your past queries,' said Garg. 'Current privacy protections, though adequate for now, may not be equipped to deal with each new future scenario.' India's data protection law For now, personal data processed by chatbots is governed by the Information Technology Act framework and Sensitive Personal Data Rules, 2011. Section 5 of the sensitive data rules says that companies must obtain consent in writing before collecting or using sensitive information. According to the rules, information relating to health and mental health conditions are considered sensitive data. There are also specialised sectoral data protection rules that apply to regulated entities like hospitals. The Digital Personal Data Protection Act, passed by Parliament in 2023, is expected to be notified soon. But it exempts publicly available personal data from its ambit if this information has voluntarily been disclosed by an individual. Given the black market of data intermediaries that publish large volumes of personal information, it is difficult to tell what personal data in the public domain has been made available 'voluntarily'. The new data protection act does not have different regulatory standards for specific categories of personal data – financial, professional, or health-related, Garg said. This means that health data collected by AI tools in India will not be treated with special sensitivity under this framework. 'For instance, if you search for symptoms on Google or visit WebMD, Google isn't held to a higher standard of liability just because the content relates to health,' said Garg. WebMD provides health and medical information. It might be different for AI tools explicitly designed for mental healthcare – unlike general-purpose models like ChatGPT. These, according to Garg, 'could be made subject to more specific sectoral regulations in the future'. However, the very logic on which AI chatbots function – where it responds based on user data and inputs – could itself be a privacy risk. Nidhi Singh, a senior research analyst and programme manager at Carnegie India, an American think tank, said she has concerns about how tools like ChatGPT customise responses and remember user history – even though users may appreciate those functions. Singh said India's new data protection is quite clear that any data made publicly available by putting it on the internet is no longer considered personal data. 'It is unclear how this will apply to your conversations with ChatGPT,' she said. Without specific legal protections, there's no telling how an AI-driven tool will use the data it has gathered. According to Singh, without a specific rule designating conversations with generative AI as an exception, it is likely that a user's interactions with these AI systems won't be treated as personal data and consequently will not fall under the purview of the act. Who takes legal responsibility? Technology firms have tried hard to evade legal liability for harm. In Florida, a lawsuit by a mother has alleged that her 14-year-old son died by suicide after becoming deeply entangled in an 'emotionally and sexually abusive relationship' with a chatbot. In case of misdiagnosis or harmful advice from an AI tool, legal responsibility is likely to be analysed in court, said Garg. 'The developers may argue that the model is general-purpose, trained on large datasets, and not supervised by a human in real-time,' said Garg. 'Some parallels may be drawn with search engines – if someone acts on bad advice from search results, the responsibility doesn't fall on the search engine, but on the user.' Highlighting the urgent need for a conversation on sector-specific liability frameworks, Garg said that for now, the legal liability of AI developers will have to be assessed on a case-to-case basis. 'Courts may examine whether proper disclaimers and user agreements were in place,' he said. In another case, Air Canada was ordered to pay compensation to a customer who was misled by its chatbot regarding bereavement fares. The airline had argued that the chatbot was a ' separate legal entity ' and therefore responsible for its own actions. Singh of Carnegie India said that transparency is important and that user consent should be meaningful. 'You don't need to explain the model's source code, but you do need to explain its limitations and what it aims to do,' she said. 'That way, people can genuinely understand it, even if they don't grasp every technical step.' AI, meanwhile, is here for the long haul. Until India can expand its capacity to offer mental health services to everyone, Singh said AI will inevitably fill that void. 'The use of AI will only increase as Indic language LLMs are being built, further expanding its potential to address the mental health therapy gap,' she said.
The Hindu
4 hours ago
- The Hindu
Simpler tests could slash biosimilar costs, widen patient access
Most of the drugs that we consume are called 'small molecule drugs'. Their chemical structure is reasonably simple. Disprin, for instance, has a molecular weight of around 180 daltons. There is another breed of drugs that are very large, complex molecules. For instance, the molecular weight of insulin is around 5,800 daltons and that of the monoclonal antibody remicade, about 150,000 daltons. (One dalton is equal to one-12th the mass of a carbon-12 atom.) Small molecule drugs also tend to have fixed structures that do not change for the duration of their use. In contrast, the complex molecules, which we call biologics, are produced in biological systems and therefore during their production slight variations in the structure may arise. However, these variations may have no impact on the stability of the molecule, its efficacy or its side effects. When a company produces a small molecule drug for the first time, it seeks patent protection for that drug. That is, no competitor may make that drug for several years. It is only when the drug goes 'off patent' that competitors may make it. In the absence of competition, the originator company can price the drug very high. Once there is competition, the competitor companies produce generics, which are copies of the original drug. They don't undertake the research and development to make the drug and they may not spend as much on marketing and sales, so the costs of generics are also much lower. Most of the drugs that you and I take are generics and are priced very cheaply compared to the originator drug. A good example is Sovaldi, a drug used to treat hepatitis C: it originally cost $84,000 for a 12-week course in the US but that dropped to $1,000 once Indian generic firms started making it. Largely it is generic drugs that keep us in India alive and well. Since biologics made by a generic firm will be produced by different biological systems, they may not be identical to those made by the originator company. Thus they are called biosimilars, not generics. For many years, a debate has raged over how much proof is required for a manufacturer to prove that a given biosimilar will work as well as the original biologic drug. Therefore, whereas much simpler testing was required to show that a generic small molecule was working like the originator molecule, there are more elaborate and expensive tests for biosimilars. Major drug regulators such as those of the US, the UK, and in Europe have been working to determine how they can simplify the requirements for approving a biosimilar, in view of the availability of modern analytical techniques. For example, the UK has removed animal trials and the US has planned to replace them with more human-relevant methods (like using organoids). In India, this requirement has not yet been updated although there is a proposal to waive animal studies on a case-by-case basis. Some have also argued that India should follow the practices of the UK and the US. The same holds for the more expensive clinical trials, which in the UK are currently required only in certain cases. Biosimilars need to be made less expensively while ensuring efficacy and minimal adverse effects. The larger the number of affordable biosimilars, the more options we will have for our patients. Gayatri Saberwal is a consultant at the Tata Institute for Genetics and Society.
Time of India
6 hours ago
- Time of India
At PGI, new hope to rein in type-2 diabetes
1 2 Chandigarh: Type 2 diabetes mellitus (T2DM) may not be invincible after all. Researchers are exploring the possibility of achieving remission through a combination of medication and lifestyle changes. The study, 'DiaRem-1' – recently published in the 'Indian journal of endocrinology and metabolism' – challenges the traditional view that T2DM is a permanent condition and provides evidence that remission is a feasible goal for some patients. The DiaRem-1 trial was an open-label, randomised controlled study at a single centre in India. It involved adult patients with T2DM of less than five years duration and an HbA1c level below 8.5% All participants were medicated for three months, followed by a three-month off-treatment period to assess for remission. Remission was officially defined as maintaining an HbA1c below 6.5% without any antidiabetic medication for three months. Nearly a third of the patients achieved remission. This small but powerful trial offers a cost-effective and scalable strategy that can work in outpatient clinics across India and the world. "With early, intensive treatment and continued support, many patients may no longer need diabetes medication. That's a powerful message of hope," said Dr Rama Walia, lead investigator of the study, adding: "Physical workout for an hour daily, including brisk walk, yoga or dance, was advised in the trial. Patients were kept on home-based healthy diet." Unlike other methods that rely on intensive, impractical diets or expensive surgeries, this study focused on using modern, widely available medications along with standard dietary and physical activity advice. Doctors now understand that two major culprits drive diabetes progression: glucotoxicity (too much sugar damaging beta cells) and lipotoxicity (fat accumulation impairing insulin action). By reversing these with medication and lifestyle therapy, the pancreas gets a much-needed break and, in some cases, begins to function more normally again. SWEAT & DIET MAY KEEP PILLS AWAY Chandigarh is considered the diabetic capital of India as the prevalence of prediabetes and diabetes is the highest in the country How Test Was Conducted Participants were divided into two groups: Intervention arm: 14 patients received a combination of liraglutide, dapagliflozin, and metformin. Control arm: 15 patients received vildagliptin, glimepiride, and metformin. Definition of Remission: HbA1c <6.5% for at least 3 months without medication Key Findings Remission Rate: 9 of the 29 participants (31%) achieved remission. Four from the intervention arm and five from control arm maintained HbA1c below 6.5% without treatment Weight Loss: Both groups experienced significant weight loss, as well as reductions in fat mass and body fat percentage. Intervention group had a median weight loss of -4.9 kg and the control group -3 kg, No Special Meds: Both modern and standard drugs helped when tightly managed Hope Floats: Not a cure, but a realistic and hopeful path to freedom from drugs Any Predictors Of Success? No baseline characteristics could be identified to predict which patients would achieve remission. However, those who did achieve remission tended to have a shorter duration of diabetes and greater weight loss. What's Next? PGI team is continuing research to test how long remission lasts and whether longer treatment duration might improve outcomes further Get the latest lifestyle updates on Times of India, along with Friendship Day wishes , messages and quotes !
